Please login to the form below

Not currently logged in
Email:
Password:

Artios Pharma

This page shows the latest Artios Pharma news and features for those working in and with pharma, biotech and healthcare.

DNA damage specialists Artios Pharma raises $84m

DNA damage specialists Artios Pharma raises $84m

DNA damage specialists Artios Pharma raises $84m. Team behind development of Lynparza focus on next-gen DDR inhibitors. ... Cambridge, UK-based Artios Pharma has raised $84 million (£65 million) in a series B financing.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest appointments

  • Artios Pharma appoints science strategy VP Artios Pharma appoints science strategy VP

    Artios Pharma appoints science strategy VP. Francis Crick Institute lead Dr Simon Boulton joins management team. ... Cambridge, UK-based Artios Pharma has appointed Dr Simon Boulton as vice president of science strategy.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics